Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma HELP
Based on 34,116 articles published since 2008
|||| 19 

These are the 34116 published articles about Melanoma that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
251 Editorial Should patients being considered for surgical management in melanoma centers have their histology reviewed by specialized pathologists? 2014

Cochran, Alistair J. ·Pathology, Laboratory Medicine and Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA, acochran@mednet.ucla.edu. ·Ann Surg Oncol · Pubmed #24728821.

ABSTRACT: -- No abstract --

252 Editorial Thank you for your support! 2014

Bosenberg, Marcus. · ·Pigment Cell Melanoma Res · Pubmed #24725267.

ABSTRACT: -- No abstract --

253 Editorial Melanoma resistance: a bright future for academicians and a challenge for patient advocates. 2014

Slominski, Andrzej T / Carlson, J Andrew. ·Department of Pathology and Laboratory Medicine, University of Tennessee Health Sciences Center, Memphis, TN; Department of Medicine, University of Tennessee Health Sciences Center, Memphis, TN. Electronic address: aslominski@uthsc.edu. · Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY. ·Mayo Clin Proc · Pubmed #24684870.

ABSTRACT: -- No abstract --

254 Editorial Nivolumab: promising survival signal coupled with limited toxicity raises expectations. 2014

O'Sullivan Coyne, Geraldine / Madan, Ravi A / Gulley, James L. ·National Cancer Institute, Bethesda, MD. ·J Clin Oncol · Pubmed #24590655.

ABSTRACT: -- No abstract --

255 Editorial Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. 2014

Ascierto, Paolo A / Margolin, Kim. ·Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione "G. Pascale", Naples, Italy. ·Cancer · Pubmed #24577788.

ABSTRACT: -- No abstract --

256 Editorial Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology. 2014

Swanton, C / André, F / Mardis, E. ·Cancer Research UK London Research Institute, London. ·Ann Oncol · Pubmed #24569915.

ABSTRACT: -- No abstract --

257 Editorial Enhancing skin cancer screening through behavioral intervention. 2014

Heckman, Carolyn J. ·Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania. ·JAMA Dermatol · Pubmed #24553600.

ABSTRACT: -- No abstract --

258 Editorial Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. 2014

Balch, Charles M / Gershenwald, Jeffrey E. ·From the University of Texas Southwestern Medical Center, Dallas (C.M.B.) · and the Department of Surgical Oncology, Melanoma and Skin Center, University of Texas M.D. Anderson Cancer Center, Houston (J.E.G.). ·N Engl J Med · Pubmed #24521113.

ABSTRACT: -- No abstract --

259 Editorial Up close and personal: the challenges of precision medicine in melanoma. 2014

Smalley, Keiran S M / Weber, Jeffrey S. ·Affiliations of authors: Department of Cutaneous Oncology (KSMS, JSW), Department of Molecular Oncology (KSMS), Melanoma Research Center of Excellence (KSMS, JSW), Moffitt Cancer Center, Tampa, FL. ·J Natl Cancer Inst · Pubmed #24511111.

ABSTRACT: -- No abstract --

260 Editorial Controlling melanoma at local and systemic levels: is a combination of ablative therapy and immunotherapy the way forward? 2014

Almeida, Joao Paulo Mattos / Drezek, Rebekah A / Foster, Aaron E. ·Department of Bioengineering, Rice University, Houston, TX, USA. ·Immunotherapy · Pubmed #24491082.

ABSTRACT: -- No abstract --

261 Editorial Precision medicine and skin cancer therapy: dealing with a moving target. 2014

Dummer, Reinhard. ·Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. ·Curr Opin Oncol · Pubmed #24469023.

ABSTRACT: -- No abstract --

262 Editorial Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe? 2014

Sloot, Sarah / Fedorenko, Inna V / Smalley, Keiran S M / Gibney, Geoffrey T. ·Moffitt Cancer Center, Department of Cutaneous Oncology , 12902 Magnolia Drive, SRB4, Tampa, FL 33612 , USA sarahsloot@gmail.com. ·Expert Opin Pharmacother · Pubmed #24456413.

ABSTRACT: The clinical development of selective BRAF inhibitors for metastatic BRAF V600 mutant melanoma patients has been a major breakthrough in targeted therapeutics. Objective response rates of approximately 50% have been observed in the Phase III studies of the BRAF inhibitors vemurafenib and dabrafenib. The side effects can be relatively common, including proliferative skin toxicities. The latter range from hyperkeratosis and keratoacanthomas (KAs) to squamous cell carcinomas (SCCs) and new primary melanomas. In addition, case reports on the emergence of gastric/colonic polyps and RAS mutant malignancies have been described during BRAF inhibitor therapy. These events have been attributed to paradoxical activation of the MAPK pathway in BRAF wild-type cells exposed to selective BRAF inhibitors in addition to increased RAS activity. Combined BRAF and MEK inhibition appears to improve clinical outcomes and reduce cutaneous proliferation events as fewer KAs and SCCs have been observed with combination therapy. Next-generation pan-RAF inhibitors ('paradox breakers') and ERK inhibitors may further enhance clinical activity in metastatic BRAF-mutant melanoma patients and mitigate this paradoxical oncogenesis. Further investigation into the potential long-term effects of selective BRAF inhibitors is warranted as expanded use of these agents is expected in patients with BRAF-mutant melanoma and other malignancies.

263 Editorial Opening the melanoma black box. 2014

Tsao, H. ·Department of Dermatology, Massachusetts General Hospital, Boston, MA, U.S.A. htsao@partners.org. ·Br J Dermatol · Pubmed #24443911.

ABSTRACT: -- No abstract --

264 Editorial Local and regional therapies for melanoma: many arrows in the quiver. 2014

Thompson, John F. ·Melanoma Institute Australia, North Sydney, New South Wales, Australia. ·J Surg Oncol · Pubmed #24419862.

ABSTRACT: -- No abstract --

265 Editorial DNp73: oncotarget in invasion and metastasis. 2014

Pützer, Brigitte M. ·Institure of Experimental Gene Therapy and Cancer Research, Rostock University Medical Center, Rostock, Germany. ·Oncotarget · Pubmed #24398448.

ABSTRACT: -- No abstract --

266 Editorial Plasticity of melanoma and EMT-TF reprogramming. 2014

Tulchinsky, Eugene / Pringle, J Howard / Caramel, Julie / Ansieau, Stéphane. ·Department of Cancer Studies and Molecular Medicine, University of Leicester, RKCSB, LRI, Leicester, UK. ·Oncotarget · Pubmed #24369126.

ABSTRACT: -- No abstract --

267 Editorial Melanoma in mankind's best friend. 2014

Bosenberg, Marcus / Arnheiter, Heinz / Kelsh, Robert. · ·Pigment Cell Melanoma Res · Pubmed #24344626.

ABSTRACT: -- No abstract --

268 Editorial Adjuvant interferon in melanoma: is duration of therapy important? 2014

McArthur, Grant A. ·Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria, Australia. ·J Clin Oncol · Pubmed #24344216.

ABSTRACT: -- No abstract --

269 Editorial Melanoma in childhood: changing our mind-set. 2013

Silverberg, Nanette B / McCuaig, Catherine C. ·Department of Dermatology, St. Luke's-Roosevelt Hospital Center, 1090 Amsterdam Ave, Ste 11D, New York, NY 10025, USA. nsilverb@chpnet.org. ·Cutis · Pubmed #24343205.

ABSTRACT: -- No abstract --

270 Editorial [BRAF: the pathologist's favorite oncogene]. 2013

Sabourin, Jean-Christophe. ·Service de pathologie, pôle de biologie clinique, pathologie, physiologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France. Electronic address: jean-christophe.sabourin@chu-rouen.fr. ·Ann Pathol · Pubmed #24331718.

ABSTRACT: -- No abstract --

271 Editorial Guidelines of care for the management of primary cutaneous melanoma. 2013

Johnson, Timothy M. ·Departments of Dermatology, Otolaryngology, and Surgery (Division of Plastic Surgery), University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan. Electronic address: timjohn@med.umich.edu. ·J Am Acad Dermatol · Pubmed #24238159.

ABSTRACT: -- No abstract --

272 Editorial Bortezomib: a therapeutic resource for the veterinary oncologist? 2013

Reisman, Scott A. ·Reata Pharmaceuticals, 2801 Gateway Dr. Ste 150, Irving, TX 75063, USA. Electronic address: scott.reisman@reatapharma.com. ·Vet J · Pubmed #24210275.

ABSTRACT: -- No abstract --

273 Editorial Who should be offered a sentinel node biopsy for melanoma less than 1 mm in thickness? 2013

Goydos, James S. ·Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway; Cancer Institute of New Jersey, New Brunswick, NJ. ·J Clin Oncol · Pubmed #24190121.

ABSTRACT: -- No abstract --

274 Editorial Does our "flight and fight" response have a link with cancer? 2013

Kohli, Manish. ·Department of Oncology, Mayo Clinic, Rochester, MN. Electronic address: kohli.manish@mayo.edu. ·Mayo Clin Proc · Pubmed #24182698.

ABSTRACT: -- No abstract --

275 Editorial Ophthalmic oncology in Nepal - an area requiring special attention. 2013

Badhu, B P. ·BP Koirala Institute of Health Sciences, Dharan, Nepal. ·Nepal J Ophthalmol · Pubmed #24172546.

ABSTRACT: -- No abstract --

Back · Next